Today: 20 May 2026
Nvidia stock climbs on China H200 demand comments as Feb. 25 earnings loom
7 January 2026
2 mins read

Nvidia stock climbs on China H200 demand comments as Feb. 25 earnings loom

NEW YORK, Jan 7, 2026, 10:21 ET — Regular session

  • Nvidia shares rose 1.8% after CEO Jensen Huang pointed to China demand and said purchase orders would signal approval for H200 chip imports.
  • Data-center cooling names stayed under pressure after Nvidia’s CES comments on lower cooling needs.
  • Traders are watching export-license timing ahead of Nvidia’s Feb. 25 results.

Shares of Nvidia (NVDA.O) rose 1.8% to $190.55 in morning trade on Wednesday after CEO Jensen Huang said purchase orders — not public announcements — would show when Chinese buyers can bring in the company’s H200, an artificial-intelligence (AI) data-center chip.

That matters because China has been a swing factor for the AI chip leader, and investors have been trying to map how much of that demand can actually turn into shipments. The H200 sits behind U.S. export licenses — approvals Washington must grant before the chips can be shipped.

The comments also land in the middle of the CES news cycle in Las Vegas, where chipmakers are racing to pitch faster systems and lower operating costs. For investors, “more efficient” can be good news for margins, but it can also shuffle winners and losers across the supply chain.

Huang told reporters he was not expecting “any press releases or any large declarations” from China on the H200, describing purchase orders as the real proof of approval. Nvidia CFO Colette Kress, speaking earlier in a JPMorgan interview, said the U.S. government was “working feverishly” on license applications, but the company still did not know when approvals would arrive.

Nvidia also used CES to lay out its next “Vera Rubin” platform — a six-chip package that underpins its next generation of AI systems — and said it is already in full production, with a debut expected later this year. Huang said he was looking for a “really giant year” with chipmaker TSMC, which makes most of Nvidia’s processors.

The promise of cooler-running chips has been less kind to parts of the AI infrastructure trade. Trane Technologies (TT.N) was down 1.6% and nVent Electric (NVT.N) slid 2.4%, while Johnson Controls (JCI.N) eased 0.2% and Carrier Global (CARR.N) gained 0.7%; Barclays analysts led by Julian Mitchell said “one should not take their comments lightly” given Nvidia’s weight in the AI ecosystem. Barclays estimated data centers are a low-double-digit share of sales for Johnson Controls and about 10% and 5% for Trane and Carrier, respectively. Reuters

Rival Advanced Micro Devices (AMD.O) fell 1.9% after it showcased new AI chips at CES and previewed its MI500 line, which it said would launch in 2027. AMD has pitched its October deal to supply OpenAI as a foothold against Nvidia’s lead in data-center AI chips.

But the China trade has moving parts. Licenses can drag, and customers can pause orders if they think rules will shift again; any hint of softer data-center spending would weigh on a stock priced for rapid growth.

Nvidia’s investor relations calendar lists its fourth-quarter fiscal 2026 results for Feb. 25, a date likely to sharpen questions on China license timing, supply constraints for Blackwell — its current flagship chip line — and how quickly Rubin systems can roll out.

Stock Market Today

  • Trump's Truth Social Withdraws Bitcoin and Bitcoin-Ethereum ETF Applications Amid Market Pressure
    May 20, 2026, 7:22 AM EDT. Trump Media & Technology Group has withdrawn its applications for Bitcoin and Bitcoin-Ethereum exchange-traded funds (ETFs), citing a strategic shift to pursue a different regulatory framework under the Investment Company Act of 1940 ('40 Act) instead of the Securities Act of 1933 ('33 Act). Yorkville America, the investment advisor, highlighted that the '40 Act allows more flexible investment strategies. This move comes amid intense fee competition in the U.S. spot Bitcoin ETF market, valued at $57.4 billion since January 2024, following Morgan Stanley's MSBT launch, which offers a low 0.14% expense ratio. The withdrawal underscores heightened competition and evolving regulatory approaches in the crypto ETF space.

Latest articles

InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested

InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested

20 May 2026
InMed Pharmaceuticals shares fell 14.4% to $1.37 in early pre-market trading Wednesday, after surging 135% Tuesday on news of an all-stock merger with Mentari Therapeutics and a planned $290 million private placement. Pre-merger InMed shareholders are expected to own about 1.51% of the combined company, which will operate as Mentari Therapeutics and focus on migraine drug development.
Micware Shares Swing Pre-Market After 26% Drop on Nasdaq Debut

Micware Shares Swing Pre-Market After 26% Drop on Nasdaq Debut

20 May 2026
Micware shares jumped 97.7% to $9.33 in premarket U.S. trading Wednesday, rebounding above last week’s $8 IPO price after closing Tuesday at $4.72. A new SEC filing showed Toyota owns 11.6% of Micware’s ordinary shares. The Japanese automotive software firm raised $22.8 million in its Nasdaq debut last week.
Dow edges up while Nasdaq falls as bond worries drag on

Futures Edge Higher Ahead of Nvidia Earnings as Wall Street Watches Key Report

20 May 2026
Nasdaq 100 futures rose 0.73% and S&P 500 futures gained 0.35% ahead of Wednesday’s open, with Nvidia set to report earnings after the close. Options markets priced in a 6.5% swing for Nvidia, equal to about $355 billion in market value. In premarket trading, Nvidia shares rose 1.84%, while Micron, Intel, and AMD also advanced. Fed minutes are due at 2:00 p.m. EDT.
Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says
Previous Story

Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings
Next Story

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

Go toTop